DLA Piper Canada advised Revive Therapeutics on $23 million short form prospectus offering

On February 12, 2021, Revive Therapeutics Ltd. (“Revive”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company, announced that it had closed a bought deal prospectus offering for $23 million. DLA Piper Canada acted for Revive in this transaction.‎

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders. It is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the Food and Drug Administration in the United States. Revive intends to use the net proceeds of the offering for Phase 3 ‎clinical costs for Bucillamine for COVID-19, Phase 1 clinical ‎costs for Psilocybin for methamphetamine use disorder ‎study, and other Psychedelic formulation development work. ‎